Genomic profiling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

• DOI: 10.1126/scitranslmed.aai7993
• Publication Date: 2017-08-09T18:40:23Z
• Authors: Jennifer M. Giltnane; Katherine E. Hutc...; Thomas P. Stricker; Luigi Formisano; Christian D. Young; Monica V. Estrada; Mellissa J. Nixon; Liping Du; Violeta Sanchez; Paula Gonzalez Er...; Maria G. Kuba; Melinda E. Sanders; Xinmeng J. Mu; Eliezer M. Van Allen; Nikhil Wagle; Ingrid A. Mayer; Vandana Abramson; Henry Gόmez; Monica Rizzo; Weiyi Toy; Sarat Chandarlapaty; Erica L. Mayer; Jason Christiansen; Danielle Murphy; Kerry Fitzgerald; Kai Wang; Jeffrey S. Ross; Vincent A. Miller; Phillip J. Stephens; Roman Yelensky; Levi Garraway; Yu Shyr; Ingrid Meszoely; Justin M. Balko; Carlos L. Arteaga
• Keywords: 0303 health sciences; drug resistance; Receptor, ErbB-2; Cyclin-Dependent Kinase 4; Breast Neoplasms; Oncology, drug resistance, Estrogen Receptor, Breast Cancer; Cyclin-Dependent Kinase 6; In Vitro Techniques; 3. Good health; 03 medical and health sciences; Oncology; Receptors, Estrogen; Cell Line, Tumor; Breast Cancer; Humans; Cyclin D1; Female; Receptor, Fibroblast Growth Factor, Type 1; Estrogen Receptor

Genomic profiling of ER + /HER2 − breast tumors after short-term estrogen deprivation revealed alterations associated with intrinsic resistance and provided mechanistic insights.